Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · IL0011319527 TA Manufacturing
Open in API
Filings indexed 485 across all filing types
Latest filing 2025-11-24 Regulatory Filings
Country IL Israel
Listing TA ENLV

About Enlivex Therapeutics Ltd.

https://enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage macrophage reprogramming immunotherapy company. It is focused on developing Allocetra™, a universal, off-the-shelf cell therapy designed to treat immune system dysregulation. The therapy works by reprogramming macrophages to resolve hyper-inflammation. Enlivex is evaluating Allocetra™ in clinical trials for the treatment of multiple indications, including acute inflammatory diseases such as sepsis and chronic inflammatory conditions like osteoarthritis. The product candidate offers flexible administration options, including systemic intravenous infusion and targeted local injections.

Recent filings

Filing Released Lang Actions
Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis
Regulatory Filings Classification · 1% confidence The document is a short, standardized notification from Enlivex Therapeutics Ltd to the Israel Securities Authority. It explicitly states 'Attached hereto is a report on 6k' and provides a filename for the attachment. According to the 'Menu vs Meal' rule, since this is a short announcement of a report being filed rather than the 6-K report itself, it is classified as a Report Publication Announcement.
2025-11-24 English
Results of a meeting held on November 7, 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is a Form 6-K filed with the SEC, which reports the results of the company's Annual General Meeting (AGM) held on November 17, 2025. It explicitly states that shareholders voted on and approved the proposals described in the previously filed Proxy Statement. Since the primary purpose of this filing is to announce the official outcome of the shareholder votes at the AGM, it falls under the category of Declaration of Voting Results.
2025-11-18 English
Results of a meeting held on November 7, 2025
Regulatory Filings Classification · 1% confidence The document is a short notification from Enlivex Therapeutics Ltd submitted to the Israel Securities Authority. It explicitly states 'Attached hereto is a report on 6k' and provides a filename '6k18112025_isa.pdf'. According to the 'Menu vs Meal' rule, since this is a short announcement stating that a report is attached rather than the report itself, it is classified as a Report Publication Announcement (RPA).
2025-11-18 English
Report of Periodic or Interim Report
Interim / Quarterly Report Classification · 1% confidence The document is a Form 6-K filed with the SEC by Enlivex Therapeutics Ltd. It contains unaudited condensed consolidated financial statements for the three and nine-month periods ended September 30, 2025. Since it provides comprehensive financial data for an interim period (quarterly/nine-month), it is classified as an Interim/Quarterly Report (IR) rather than a general regulatory filing, as it meets the criteria for substantive financial reporting. 9M 2025
2025-11-15 English
Report of Periodic or Interim Report
Report Publication Announcement Classification · 1% confidence The document is a short notification from Enlivex Therapeutics Ltd submitted to the Israel Securities Authority. It explicitly states 'Attached hereto is a report on 6k' and provides a filename for the attachment. According to the 'Menu vs Meal' rule, a document that announces the publication or attachment of another report is classified as a Report Publication Announcement (RPA).
2025-11-15 English
Immediate Report of Meeting
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a proxy card for an Annual General Meeting (AGM). It contains specific voting instructions for the election of directors, approval of share capital increases, and appointment of auditors. This material is sent to shareholders to solicit their votes for the upcoming meeting, which fits the definition of a Proxy Solicitation & Information Statement (PSI).
2025-11-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.